ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference in New York, NY. The presentation is scheduled for June 7, 2023 at 9:00 am ET.

A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.90
-3.13 (-1.41%)
AAPL  260.29
-2.48 (-0.95%)
AMD  238.13
+0.10 (0.04%)
BAC  51.27
-0.25 (-0.48%)
GOOG  256.67
+5.33 (2.12%)
META  738.50
+5.23 (0.71%)
MSFT  522.47
+4.81 (0.93%)
NVDA  183.00
+1.84 (1.02%)
ORCL  276.20
+1.05 (0.38%)
TSLA  442.01
-0.59 (-0.13%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.